At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 321 enrolled
Drug / intervention
GTx-024 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase III, Randomized, Double-Blind, Placebo Controlled Study of the Effect of GTx-024 on Muscle Wasting in Patients With Non-Small Cell Lung Cancer on First Line Platinum Plus a Taxane Chemotherapy
In Brief
A Phase 3 clinical trial evaluating GTx-024 and placebo for Muscle Wasting and Non Small Cell Lung Cancer. Completed, enrolled 321 participants across 27 sites.
Detailed Summary
The purpose of this study is to determine if the investigational drug GTx-024 can help subjects with non-small cell lung cancer increase physical function and maintain or gain muscle, also called "lean body mass".
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMuscle Wasting, Non Small Cell Lung Cancer
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2011201220132014201520162017201820192020202120222023202420252026
First PostedMay 2011
Enrollment StartJul 2011
Primary CompletionMay 2013
Study CompletionJun 2014
TodayJul 2026
First PostedMay 18, 2011
Enrollment StartJul 1, 2011
Primary CompletionMay 1, 2013
Study CompletionJun 1, 2014
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 15.1 years ago
Interventions
GTx-024drug
subjects will be randomized to receive GTx-024 for the full duration of the trial.
placebodrug
subject will receive placebo for the duration of the trial